Medifast announces partnership with The V Foundation for Cancer Research
As part of this multi-faceted partnership with The V Foundation, Medifast will fund research grants that explore the link between obesity and cancer and the impact of healthy
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
BMN 250 is a new fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2). The company has also started IND-enabling studies and intends